ReviewCurrent opinion in HIV and AIDS2014
Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?
Review in Current opinion in HIV and AIDS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4.AIDS (London, England) · 2015Trial
- Prevalence of cardiometabolic syndrome in HIV-infected persons: a systematic review.Journal of diabetes and metabolic disorders · 2020Review
- Why Do People Living with HIV Adhere to Antiretroviral Therapy and Not Comorbid Cardiovascular Disease Medications? A Qualitative Inquiry.Patient preference and adherence · 2020Article
- Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD).American heart journal · 2019Article
- Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.Circulation · 2019Review
- Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection.Current cardiology reviews · 2018Review
- HIV-1-Associated Atherosclerosis: Unraveling the Missing Link.Journal of the American College of Cardiology · 2017Review
- Population-level decline in BMI and systolic blood pressure following mass HIV treatment: Evidence from rural KwaZulu-Natal.Obesity (Silver Spring, Md.) · 2017Article
- The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population.BMC public health · 2016Article
- Cardiovascular Disease, Statins, and HIV.The Journal of infectious diseases · 2016Review
- Complications of Treatment in Youth with HIV.Current HIV/AIDS reports · 2016Review
- Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy.HIV clinical trials · 2016Article
- Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.Oral diseases · 2016Article
- Immune activation and cardiovascular disease in chronic HIV infection.Current opinion in HIV and AIDS · 2016Review
- Article
- Statins to improve cardiovascular outcomes in treated HIV infection.Current opinion in infectious diseases · 2016Review
- HIV infection induces structural and functional changes in high density lipoproteins.Atherosclerosis · 2015Article
- Acute Spontaneous Coronary Artery Thrombosis as Initial Presentation of HIV Infection in a Young Man.Case reports in cardiology · 2015Article
- Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults.Clinical cardiology · 2014Article
- Preventing Heart Failure in Inflammatory and Immune Disorders.Current cardiovascular risk reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewInflammation and immune activation associated with untreated HIV infection may increase the risk for cardiovascular disease (CVD) and are not entirely reversed by antiretroviral therapy (ART). Although older ART regimens were associated with drug-specific risks for CVD, this may not be true for modern ART. Thus, with regard to CVD risk, the net benefit of initiating ART at higher CD4 T-cell counts remains unclear. RECENT
findingsIn addition to the well established risk of coronary heart disease, emerging evidence now suggests that chronic HIV infection is associated with higher risk of ischemic stroke, heart failure, and arrhythmias. These epidemiologic studies have associated immunodeficiency and active viral replication with higher CVD risk. Novel methods of imaging subclinical vascular disease continue to implicate inflammation and immune activation as likely mediators of CVD among patients with HIV. Newer generation protease inhibitors, chemokine receptor 5 antagonists, and integrase inhibitors do not appear to be associated with the adverse cardiometabolic risks of older drugs. SUMMARY: Recent evidence suggests that treating HIV infection with ART may reduce the risk of CVD, even at higher CD4 T-cell counts; however, the definitive answer to this question will come from clinical trials and long-term observational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.